Chemomab Therapeutics Ltd
CMMB
Company Profile
Business description
Chemomab Therapeutics Ltd is a clinical-stage biotech company, focusing on the discovery and development of therapeutics for fibrosis-related diseases with large unmet needs. The company's candidate, CM-101, is a monoclonal antibody that targets CCL24 and was shown to interfere with the underlying biology of liver, skin, and lung fibrosis using a novel and differentiated mechanism of action. CM-101 has demonstrated the potential to treat multiple severe and life-threatening fibrotic and inflammatory diseases. It is advancing three Phase 2 clinical trials in parallel for CM-101, treating rare fibrotic conditions.
Contact
Kiryat Atidim
Building 7
Tel Aviv6158002
ISRT: +972 773310156
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 December 2025
Employees
16
Stocks News & Analysis
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 8,467.00 | 4.40 | 0.05% |
| CAC 40 | 7,853.56 | 109.81 | 1.42% |
| DAX 40 | 23,734.73 | 235.41 | 1.00% |
| Dow JONES (US) | 41,249.38 | 119.07 | -0.29% |
| FTSE 100 | 8,585.80 | 31.00 | 0.36% |
| HKSE | 23,549.46 | 681.72 | 2.98% |
| NASDAQ | 17,928.92 | 0.78 | 0.00% |
| Nikkei 225 | 37,644.26 | 140.93 | 0.38% |
| NZX 50 Index | 12,676.75 | 71.68 | 0.57% |
| S&P 500 | 5,659.91 | 4.03 | -0.07% |
| S&P/ASX 200 | 8,233.50 | 2.30 | 0.03% |
| SSE Composite Index | 3,369.24 | 27.25 | 0.82% |